Ying Huang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/127032/publications.pdf

Version: 2024-02-01

		1478505	1720034	
7	470	6	7	
papers	citations	h-index	g-index	
7 all docs	7 docs citations	7 times ranked	623 citing authors	

#	Article	IF	CITATIONS
1	Preclinical pharmacokinetics and metabolism of MAK683, a clinical stage selective oral embryonic ectoderm development (EED) inhibitor for cancer treatment. Xenobiotica, 2022, 52, 65-78.	1.1	6
2	Discovery of the Clinical Candidate MAK683: An EED-Directed, Allosteric, and Selective PRC2 Inhibitor for the Treatment of Advanced Malignancies. Journal of Medicinal Chemistry, 2022, 65, 5317-5333.	6.4	24
3	An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED. Nature Chemical Biology, 2017, 13, 381-388.	8.0	259
4	Discovery of First-in-Class, Potent, and Orally Bioavailable Embryonic Ectoderm Development (EED) Inhibitor with Robust Anticancer Efficacy. Journal of Medicinal Chemistry, 2017, 60, 2215-2226.	6.4	86
5	Split luciferase-based biosensors for characterizing EED binders. Analytical Biochemistry, 2017, 522, 37-45.	2.4	7
6	Structure-Guided Design of EED Binders Allosterically Inhibiting the Epigenetic Polycomb Repressive Complex 2 (PRC2) Methyltransferase. Journal of Medicinal Chemistry, 2017, 60, 415-427.	6.4	52
7	Discovery and Molecular Basis of a Diverse Set of Polycomb Repressive Complex 2 Inhibitors Recognition by EED. PLoS ONE, 2017, 12, e0169855.	2.5	36